Management of Recurrent Optic Neuritis in MOGAD
For recurrent optic neuritis in MOGAD, initiate chronic immunosuppressive therapy with rituximab as first-line maintenance treatment, combined with prolonged corticosteroid therapy (>5 weeks) following acute attacks to prevent relapses and preserve long-term visual function.
Acute Attack Management
When a patient presents with recurrent optic neuritis in MOGAD, treat the acute episode aggressively:
- Administer high-dose intravenous methylprednisolone (1000 mg daily for 5 days) as initial therapy 1, 2
- If the patient is unresponsive to corticosteroids (vision not improving after 3-5 days), proceed immediately to plasmapheresis 3
- Following acute treatment, use a prolonged oral corticosteroid taper extending beyond 5 weeks, as this is associated with favorable long-term prognosis 4
Chronic Immunosuppression for Relapse Prevention
The critical decision point is recognizing that recurrent optic neuritis in MOGAD requires long-term immunosuppression:
First-Line Maintenance Therapy
Rituximab is the preferred agent for preventing relapses in MOGAD with recurrent optic neuritis 3, 1. The evidence shows:
- A patient with corticosteroid-unresponsive bilateral recurrent ON achieved complete remission for 2 years on rituximab 3
- Rituximab is among the most commonly utilized treatments for relapsing MOGAD 1
Alternative Immunosuppressive Options
If rituximab is contraindicated or unavailable, consider these alternatives in order of preference:
- Azathioprine - effective in maintaining remission 3, 1
- Mycophenolate mofetil - commonly used with good efficacy 1, 5
- Monthly intravenous immunoglobulin (IVIG) 1
Steroid-Dependent Disease
Some patients require low-dose maintenance corticosteroids in combination with steroid-sparing agents 5. One case remained relapse-free for 2 years on low-dose steroids plus mycophenolate after relapsing when steroids were discontinued 5.
Refractory Cases
For patients failing multiple conventional immunosuppressants (corticosteroids, IVIG, azathioprine, mycophenolate, and rituximab), consider:
Tocilizumab (IL-6 receptor inhibitor) - emerging evidence shows subcutaneous tocilizumab can achieve remission in treatment-resistant MOGAD with recurrent optic neuritis, allowing successful steroid reduction 6
Risk Stratification
Identify patients at highest risk for recurrence who need more aggressive maintenance therapy:
- Visual impairment at presentation increases recurrence risk 4-fold (OR: 4.22) 4
- Age <8 years at onset predicts recurrent optic neuritis 4, 7
- Higher EDSS scores at discharge and multiple previous episodes predict poor long-term outcomes 4
Critical Pitfalls to Avoid
- Do not use interferon-beta or natalizumab - these MS therapies can paradoxically increase relapse rates in MOGAD 8
- Do not undertaper corticosteroids prematurely - steroid therapy <5 weeks is associated with worse long-term prognosis 4
- Do not delay plasmapheresis in corticosteroid-unresponsive cases - waiting can result in irreversible vision loss 3
- Do not assume monophasic disease - recurrent optic neuritis is a hallmark of MOGAD and requires proactive prevention strategies 8, 1
Monitoring Strategy
- Optical coherence tomography (OCT) is valuable for monitoring disease activity and structural damage, showing increased RNFL thickness acutely and progressive thinning during follow-up 3
- Most RNFL thinning occurs in the first 6 months but continues beyond 2 years 7
- Despite significant optic atrophy, children with MOGAD-ON often return to normal visual acuity (76% achieved complete recovery in one series) 7
Prognosis
The recovery from MOG-associated optic neuritis is typically better than AQP4-positive neuromyelitis optica, with favorable overall prognosis when appropriately treated 1. However, recurrent attacks without adequate immunosuppression can lead to cumulative visual disability, making chronic preventive therapy essential for patients with relapsing disease.